Cardiac Progenitor Cell Therapy — PatSnap Eureka
Cardiac Progenitor Cell Therapy in Ischemic Heart Failure
No approved therapy restores functional myocardium after ischemic cardiomyocyte loss. PatSnap Eureka maps the c-kit+, SSEA-3/Muse, Isl1+, and epicardial progenitor pipelines — from patent filings to Phase I/IIa clinical signals — so your R&D team can act on the latest innovation intelligence.
Why Cardiac Progenitor Cells? The Case for Regenerative Intervention
Ischemic heart failure represents the end-stage consequence of cardiomyocyte loss following myocardial infarction — a condition for which no approved therapy restores functional myocardium. The adult mammalian heart has an intrinsically insufficient regenerative capacity, making exogenous or endogenously activated progenitor populations a necessary therapeutic lever. According to data tracked by the World Health Organization, cardiovascular disease remains the leading cause of death globally, underscoring the unmet need.
The molecular landscape of cardiac progenitor cell (CPC) biology centers on discrete progenitor subpopulations defined by surface markers and transcription factors. C-kit (KIT/CD117), a receptor tyrosine kinase, is the most frequently cited marker in the academic literature — it defines a resident cardiac stem cell population with demonstrated cardiomyogenic, endothelial, and smooth muscle differentiation potential. Research from the life sciences intelligence platform at PatSnap tracks this modality across preclinical and clinical patent filings globally.
The PTEN/PI3K/Akt axis governs c-kit+ CSC proliferative capacity, with miR-21 identified as a positive regulator via PTEN suppression. TGF-β acts as a suppressor of c-kit+ cell yield and function in chronic heart failure, creating a pathological feedback loop that may limit autologous product quality. NOTCH1 inhibition in the stressed heart is described as limiting fibrosis and promoting non-myocyte cells to adopt cardiomyocyte fate — a potential adjunct strategy to CPC delivery.
Patent registries at the European Patent Office contain the most active commercial filings in this space, with CLIO, INC.'s SSEA-3+ Muse cell portfolio representing the sole identified commercial IP actor in the retrieved dataset.
Six CPC Therapy Approaches: From Bench to Bedside
Patent signals and academic literature map six distinct cardiac progenitor cell strategies — each with a unique mechanism, delivery route, and development stage.
C-Kit+ Cardiac Stem Cell Therapy
Isolated from right atrial appendage tissue during cardiac surgery, expanded ex vivo, and redelivered intracoronarily or intramyocardially. The SCIPIO trial (University of Louisville) demonstrated safety and promising LVEF improvement and infarct mass reduction at Phase I interim analysis. Intracoronary infusion of up to 20 million c-kit+ human CSCs was shown to be hemodynamically tolerable in pigs. Epigenetic augmentation via class I HDAC inhibition (mocetinostat) and HO-1 preconditioning (cobalt protoporphyrin) represent next-generation optimization strategies for this modality.
SCIPIO Phase I · PTEN/PI3K/Akt · HDAC inhibitionSSEA-3+ Pluripotent Muse Cell Therapy
Two active European patent filings from CLIO, INC. claim cell preparations containing SSEA-3-positive Muse (Multilineage-differentiating Stress-Enduring) cells isolated from mesenchymal tissue. Following intravenous administration, Muse cells are described as selectively accumulating at damaged myocardial tissue and differentiating into cardiac muscle in situ — a homing mechanism driven by damage signals. This IV delivery approach is mechanistically distinct from direct intramyocardial delivery. The 2019 EP filing and a 2023 continuation maintain active legal status; a 2018 Singapore filing is inactive.
CLIO, INC. · EP 2019 + 2023 Active · IV homingIsl1+ Embryonic Progenitors in Biomaterial Scaffolds
Isl1+ CPCs are second heart field-origin progenitors capable of differentiating into cardiomyocytes, endothelial cells, and smooth muscle cells. In a University of Macau preclinical study, Isl1+ CPCs seeded into decellularized porcine small intestinal submucosa extracellular matrix (SIS-ECM) demonstrated tri-lineage differentiation, spontaneous contraction, and β-adrenergic responsiveness in vitro, and improved infarcted heart function in vivo. The temporal restriction of Isl1 expression to embryonic stages implies therapeutic use requires iPSC-derived or embryonic-stage cell sources.
SIS-ECM scaffold · Tri-lineage · Univ. MacauCardiosphere-Derived Cell (CDC) Therapy
Cardiospheres — multicellular clusters derived from cardiac explants — and their CDCs are closely related to c-kit+ populations and enriched in endogenous cardiac progenitors. Cedars-Sinai Heart Institute published large-animal data demonstrating that percutaneous NOGA-guided transendocardial injection of allogeneic cardiospheres or CDCs increased viable myocardium, reduced scar size, and attenuated cardiac dilatation in porcine ischemic cardiomyopathy, establishing dose-response relationships across 89 minipigs.
89 minipigs · NOGA-guided · Cedars-SinaiEpicardially Delivered hiPSC-CM Constructs
A Phase I/IIa dose-escalation clinical trial protocol (Nanjing Drum Tower Hospital) covers epicardial injection of allogeneic hiPSC-derived cardiomyocytes during CABG in advanced heart failure patients. An Osaka University case report (ClinicalTrials.gov #jRCT2053190081) describes epicardial patch implantation in a patient with ischemic cardiomyopathy, with clinical-grade patches confirming cardiogenic phenotype and absence of cancer-related gene mutations. Tokyo Women's Medical University explored self-assembling peptide hydrogel (PuraMatrix) for epicardial MSC coating, showing superior cardiac function improvement versus direct injection.
Phase I/IIa · Osaka Univ. case report · PuraMatrixCPC-Derived Extracellular Vesicle Therapy
Multiple results converge on the paracrine mechanism as the primary driver of CPC therapeutic benefit rather than direct cardiomyocyte replacement. ISX-9-induced CPCs derived from iPSCs secrete extracellular vesicles (EVs) containing miRNA cargo — notably miR-373 — that promote angiogenesis, cardiomyocyte proliferation, and antifibrotic effects in the infarcted heart. This acellular approach signals a transition from cell-based to cell-free (exosome/EV) delivery as a next-generation iteration, potentially avoiding cell engraftment and survival barriers.
miR-373 · ISX-9-induced iPSC-CPCs · Acellular EVPipeline Signals: Development Stages & Molecular Target Landscape
Patent and literature analysis from PatSnap Eureka reveals the distribution of CPC therapy modalities and the key molecular targets driving the field.
CPC Therapy Modalities by Development Stage
Epicardial hiPSC-CM delivery leads clinical translation at Phase I/IIa; c-kit+ CSCs reached Phase I (SCIPIO); SSEA-3+ Muse cells are patent-protected but preclinical.
Key Molecular Targets in CPC Biology
C-Kit dominates academic literature citations; SSEA-3 is IP-protected by CLIO, INC.; Isl1, NOTCH1, CD90, and miR-21 define supporting mechanistic nodes.
Clinical Translation Timeline: Key Milestones
From SCIPIO Phase I (c-kit+) to the Osaka University hiPSC-CM case report and the Nanjing Phase I/IIa protocol — the field has moved from preclinical to active clinical investigation.
Emerging Combination & Next-Gen Strategies
Five convergent combination approaches identified across retrieved results — from epigenetic priming to acellular EV delivery and NOTCH1 pathway adjuncts.
Patent Assignees, Key Institutions & Development Signals
Innovation in this dataset is almost exclusively literature-driven. CLIO, INC. is the sole identified commercial IP actor, holding active European patent rights for SSEA-3+ Muse cells.
| Institution / Assignee | Modality Focus | Evidence Type | Development Stage | Key Contribution |
|---|---|---|---|---|
| CLIO, INC. | SSEA-3+ Muse Cells | Patent (EP 2019, 2023; SG 2018) | Patent Active | Sole commercial IP actor; IV homing mechanism; active EP prosecution |
| University of Louisville / Inst. Molecular Cardiology | C-Kit+ CSCs | Academic Literature | Phase I (SCIPIO) | SCIPIO trial; HO-1 preconditioning; 20M cell porcine safety data |
| Cedars-Sinai Heart Institute | Cardiosphere-Derived Cells | Academic Literature | Early Clinical | 89-minipig transendocardial dose-response; scar reduction; NOGA delivery |
| Osaka University Graduate School of Medicine | Epicardial hiPSC-CM | Case Report + Protocol | Phase I (Case) | First hiPSC-CM epicardial patch case report; jRCT2053190081 |
| Nanjing Drum Tower Hospital | Epicardial hiPSC-CM | Clinical Trial Protocol | Phase I/IIa | Dose-escalation CABG protocol; allogeneic hiPSC-CMs; active trial |
Track every new CPC patent filing as it publishes
PatSnap Eureka monitors 120+ patent jurisdictions and surfaces new filings relevant to your research in real time.
Four Strategic Implications for CPC Therapy Development
Derived from patent and literature signals in the PatSnap Eureka dataset — actionable intelligence for R&D and IP strategy teams.
C-Kit+ CSCs Are Transitioning to Augmented Formats
Native c-kit+ CSC therapy has plateaued in efficacy due to poor engraftment and limited cardiomyogenic commitment. IP strategies and development programs combining c-kit+ cells with epigenetic modifiers (HDAC inhibitors), microRNA agonists (miR-21), or cytoprotective preconditioning agents (HO-1 inducers) represent the most clinically proximal differentiation opportunity in this modality.
CLIO, INC.'s Muse Cell Portfolio: Underexplored IP Niche
Two active European patents with distinct claim sets around IV-administered SSEA-3+ mesenchymal Muse cells for MI and heart failure are the sole commercial IP filings recovered in this dataset. For IP strategists, this space lacks dense competing filings, signaling either early-stage exclusivity or limited competitive interest — both commercially significant positions.
From Phase I to Systematic Evidence: What the Clinical Record Shows
The SCIPIO trial (Phase I) represents the first clinical application of autologous c-kit+ CSCs in ischemic heart disease, infused intracoronarily in ischemic cardiomyopathy patients. Referenced results note safety and promising interim functional improvements — including LVEF improvement and infarct mass reduction — at the University of Louisville. No safety concerns were reported at the doses tested.
A meta-analysis of 14 eligible RCTs totaling 669 IHF patients (380 receiving stem cell transplantation) analyzed weighted mean differences for NYHA class, LVEF, and ventricular dimensions. This systematic evidence base encompasses both bone marrow-derived and cardiac-derived cell types. For context on trial registries, ClinicalTrials.gov lists current and completed cardiac cell therapy studies.
Multiple retrieved review papers note that first-generation c-kit+ based therapies showed safety with modest efficacy signals in Phase I-II, but were ultimately characterized as having poor engraftment and limited mature cardiomyocyte formation in double-blind settings — framing them as "first-generation" approaches requiring augmentation.
The Osaka University case report (ClinicalTrials.gov #jRCT2053190081) describes epicardial patch implantation of allogeneic hiPSC-CM patches in a patient with ischemic cardiomyopathy. Clinical-grade production confirmed cardiogenic phenotype and absence of cancer-related gene mutations in safety testing. PatSnap's life sciences intelligence tools can map the full hiPSC-CM patent landscape supporting this clinical program.
The Nanjing Drum Tower Hospital Phase I/IIa protocol represents an active clinical trial for epicardial injection of allogeneic hiPSC-CMs in advanced heart failure patients undergoing CABG surgery — a dose-escalation, placebo-controlled design. Regulatory frameworks for such trials are overseen by bodies including the US FDA and equivalent international authorities.
Cardiac Progenitor Cell Therapy — key questions answered
C-kit+ cardiac stem cells are isolated from right atrial appendage tissue obtained during cardiac surgery, expanded ex vivo, and redelivered intracoronarily or intramyocardially. The SCIPIO Phase I trial demonstrated safety and promising interim functional improvements including LVEF improvement and infarct mass reduction at the University of Louisville.
SSEA-3+ Muse (Multilineage-differentiating Stress-Enduring) cells are pluripotent cells isolated from biological mesenchymal tissue. Following intravenous administration, Muse cells are described as selectively accumulating at damaged myocardial tissue and differentiating into cardiac muscle in situ — a homing mechanism driven by damage signals rather than local injection. Two active European patents from CLIO, INC. cover this approach.
Transforming Growth Factor-beta (TGF-β) is identified as a suppressor of c-kit+ cell yield and function in the setting of chronic heart failure, with CHF reducing both numbers and differentiation capacity of atrial explant-derived c-kit+ progenitors. This TGF-β-dependent functional decline creates a fundamental constraint for autologous cell therapy in the target patient population.
Both academic case reports (Osaka University) and formal Phase I/IIa trial protocols (Nanjing Drum Tower Hospital) now deploy epicardial injection or patching approaches, suggesting that the field is moving beyond intracoronary infusion as the default delivery method, particularly for hiPSC-CM-based products during concomitant cardiac surgery.
Inhibition of NOTCH1 signaling in the stressed heart is described as limiting fibrosis and promoting non-myocyte cells to adopt cardiomyocyte fate, suggesting NOTCH1 as a target for combination approaches pairing cell therapy with pathway inhibition.
A meta-analysis of 14 eligible RCTs totaling 669 IHF patients (380 receiving stem cell transplantation) analyzed weighted mean differences for NYHA class, LVEF, and ventricular dimensions. Multiple retrieved review papers note that first-generation c-kit+ based therapies showed safety with modest efficacy signals in Phase I-II, but were ultimately characterized as having poor engraftment and limited mature cardiomyocyte formation in double-blind settings.
Still have questions? Let PatSnap Eureka search the cardiac progenitor cell literature for you.
Ask Eureka About CPC TherapyAccelerate Your Cardiac Regenerative Medicine Research
Join 18,000+ innovators already using PatSnap Eureka to map patent landscapes, track clinical pipelines, and identify white-space opportunities in cell therapy.
References
- Cardiac Stem Cell Therapy for Cardiac Repair — University of Louisville (2014)
- Transplantation of Epigenetically Modified Adult Cardiac c-Kit+ Cells Retards Remodeling and Improves Cardiac Function in Ischemic Heart Failure Model — Banner Sun Health Research Institute (2015)
- Safety of Intracoronary Infusion of 20 Million C-Kit Positive Human Cardiac Stem Cells in Pigs — University of Louisville (2015)
- Pluripotent stem cell that induces repair and regeneration after myocardial infarction — CLIO, INC. EP Patent (2019)
- Pluripotent stem cell that induces repair and regeneration after myocardial infarction (continuation) — CLIO, INC. EP Patent (2023)
- Pluripotent stem cell that induces repair and regeneration after myocardial infarction — CLIO, INC. SG Patent (2018, inactive)
- Transplantation of Isl1+ cardiac progenitor cells in small intestinal submucosa improves infarcted heart function — University of Macau
- miR-21 increases c-kit+ cardiac stem cell proliferation in vitro through PTEN/PI3K/Akt signaling
- Chronic Heart Failure Is Associated With Transforming Growth Factor Beta-Dependent Yield and Functional Decline in Atrial Explant-Derived c-Kit+ Cells
- Inhibition of the NOTCH1 Pathway in the Stressed Heart Limits Fibrosis and Promotes Recruitment of Non-Myocyte Cells into the Cardiomyocyte Fate
- Preconditioning Human Cardiac Stem Cells with an HO-1 Inducer Exerts Beneficial Effects After Cell Transplantation in the Infarcted Murine Heart
- Allogeneic Cardiospheres Delivered via Percutaneous Transendocardial Injection Increase Viable Myocardium, Decrease Scar Size, and Attenuate Cardiac Dilatation in Porcine Ischemic Cardiomyopathy — Cedars-Sinai Heart Institute
- Epicardial injection of allogeneic human-induced-pluripotent stem cell-derived cardiomyocytes in patients with advanced heart failure: protocol for a phase I/IIa dose-escalation clinical trial — Nanjing Drum Tower Hospital
- Case report: Transplantation of human induced pluripotent stem cell-derived cardiomyocyte patches for ischemic cardiomyopathy — Osaka University
- Self-assembling peptide hydrogel enables instant epicardial coating of the heart with mesenchymal stromal cells for the treatment of heart failure — Tokyo Women's Medical University
- miRNAs in Extracellular Vesicles from iPS-Derived Cardiac Progenitor Cells Effectively Reduce Fibrosis and Promote Angiogenesis in Infarcted Heart
- Therapeutic benefits of CD90-negative cardiac stromal cells in rats with a 30-day chronic infarct
- Spatiotemporal Transcriptomes of Pig Hearts Reveal Midkine-Mediated Vascularization in a Chronic Myocardial Infarcted Model
- Effect of stem cell transplantation on patients with ischemic heart failure: a systematic review and meta-analysis of randomized controlled trials
- Unlocking the Pragmatic Potential of Regenerative Therapies in Heart Failure with Next-Generation Treatments
- World Health Organization — Cardiovascular Disease Global Statistics
- European Patent Office — Cardiac Cell Therapy Patent Database
- ClinicalTrials.gov — Cardiac Progenitor Cell Therapy Trial Registry
- US Food and Drug Administration — Cell and Gene Therapy Regulatory Framework
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This page represents a snapshot of innovation signals within the analyzed patent and literature dataset only and should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.